ESMO 2022 | The use of radiomics to identify predictive biomarkers of immuntherapy in glioblastoma

Maximilian Mair, MD, Medical University of Vienna, Vienna, Austria, discusses the increasing interest of radiomics in neuro-oncology, specifically in terms of radiogenomics to identify predictive genetic markers of tumors. Dr Mair talks on the extension of this concept for immune markers to identify predictive radiomic markers of immunotherapy in glioblastoma. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.